Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Pathways (CLPA) -- Ignore unavailable to you. Want to Upgrade?

To: bob who wrote (35)	11/12/1998 9:28:00 AM
From: AJ Berger	Read Replies (1) \| Respond to of 566

I guess the gist of it is... Negetive: that Solomon won't be covering them, so their will be a lag period before other's gear up to cover them instead. (Longs buying into recommendation may sell or have to hold) Positive: insiders have not gotten their CLPA shares yet, so they can't sell or be borrowed to be shorted yet. (much less downside pressure on this stock for a few weeks) Positive: CellPath is doing aggressive self promotion now that they are publically traded. (that won't help too much at least until coverage begins) as for the actual drug technology itself, I will consider that a factor when they actually get approval. Either way I plan on covering my short for a tiny loss. No sense of spitting into the wind much longer. Good Luck.